Alcidion (ASX:ALC) has acquired ExtraMed
April 2021 — Alcidion (ASX:ALC) has acquired ExtraMed Ltd., a UK provider of patient flow management software that helps address key pain-points for hospital administrative staff.
Alcidion is transforming healthcare with smart, intuitive and complementary software products and services that create a unique offering in the global healthcare market. It offers solutions that support interoperability, allow communication and task management, and deliver clinical decision support at the point-of-care to improve patient systems. Alcidion has delivered strong organic growth in FY20 (with solid revenue up 33% as of Q3). The acquisition of ExtraMed will further accelerate this growth profile. This will add nine NHS trusts (six being new to Alcidion), expanding its NHS presence to 27 trusts or ~19% of target Acute NHS market, with upside revenue potential on cross-sell opportunities for Miya (its flagship product).
ExtraMed is a long-standing UK market leader in patient flow and has a 20-year track record. It specializes in providing NHS trusts with software that helps frontline staff make informed decisions based on real-time visibility of patient flow.
Our role in the transaction
Oaklins’ team in Australia acted as corporate advisor to the buyer in this transaction.
Talk to the deal team
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreRöntgeninstitut Aarau has been acquired by Evidia
The owners of Röntgeninstitut Aarau have sold the business to Evidia Group as part of their succession planning. The former owners will remain involved in the institute and support its future development alongside Evidia.
Learn moreLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn more